Four-year outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a treat-and-extend regimen in Japanese patients
Objective: The purpose of our study was to determine the 4-year visual and anatomic outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration (AMD) using a treat-and-extend (TAE) regimen. Methods: We retrospectively reviewed the medical records of 39 patients wi...
Main Authors: | Koki Ishibashi, Masatoshi Haruta, Yumi Ishibashi, Rie Noda, Shotaro Dake, Shigeo Yoshida |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-01-01
|
Series: | Therapeutic Advances in Ophthalmology |
Online Access: | https://doi.org/10.1177/2515841420984586 |
Similar Items
-
Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01) -
Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration
by: Mohamed Kamel Soliman, et al.
Published: (2021-09-01) -
Visual Findings in Neovascular Macular Degeneration Refractory to Bevacizumab after Intravitreal Aflibercept Therapy
by: Moazez, Carmel
Published: (2016) -
Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept
by: Dilan Yildiz, et al.
Published: (2021-06-01) -
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
by: Sam Razavi, et al.
Published: (2021-02-01)